Herceptin: breaking new ground.
Cohen
R L
RL
D000818:Animals; D030801:Animals, Genetically Modified; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000235:genetics / Q000628:therapy*; D002986:Clinical Trials as Topic; D015195:Drug Design; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D018734:Genes, erbB-2; D006801:Humans; D007373:Interinstitutional Relations; D008325:Mammary Neoplasms, Experimental / Q000235:genetics; D009316:National Institutes of Health (U.S.); D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology / Q000502:physiology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000276:immunology / Q000502:physiology; D012955:Societies, Medical; D000068878:Trastuzumab; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab